Abstract 570P
Background
Mismatch repair deficient or microsatellite instable (MSI) tumors are often characterized by high mutational burdens and strong immune infiltration and have shown higher sensitivity to immune checkpoint inhibitors (ICIs) compared to microsatellite stable (MSS) tumors. However, only a portion of the patients with MSI colorectal cancer (CRC) gain survival benefits from ICIs treatment, suggesting unclear heterogeneity in MSI tumors.
Methods
We analyzed the whole-genomes and transcriptomes of 223 ICIs treatment-naïve MSI CRC tumors from U-CAN project. Immune cell infiltration and cancer-relevant pathways were evaluated by CIBERSORT and PROGENy, respectively. An MSI subtyping model was developed based on ResNet50.
Results
Unsupervised classification based on gene expression data divided MSI tumors into two distinct classes (class1 and 2), with MSI class1 characterized by a lower level of chromosomal instability, a higher level of hypoxia, and more activated EGFR, JAK-STAT, TNFa, and NFkB pathways than class2. However, two MSI classes showed no differences in 5-year survival. Further investigation of the immune cell population showed that class1 had considerably higher immune cell infiltration compared to class2, specifically in M0, M1 and M2 macrophages, CD4 and CD8 T-cells, naïve B-cells, resting NK-cells, and neutrophiles. Class2 exhibited significantly higher loss in 10q23.31 (containing PTEN) and reduced expression of PTEN, which may lead to an immunosuppressive tumor microenvironment and partially explain the higher activation in PI3K and VEGF pathways in class2 compared to class1. Importantly, ICIs targets, such as CTLA4, PD-1, and PD-L1 all had higher expressions in calss1. We further developed an MSI subtyping model based on refined pathway features of normal tissue, tumors with MSS, class1 or 2. Ongoing analyses include validation of MSI classification in the TCGA dataset.
Conclusions
We illustrated the heterogeneity in MSI CRCs and revealed two subclasses of MSI with distinct molecular features, which may be informative for immune-based treatments. The MSI subtyping model may further facilitate precision immunotherapy and allow patients to derive clinical benefits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University Umeå University BGI-Shenzhen.
Funding
The Swedish Cancer Society the Uppsala Cancer Foundation the Guangdong Provincial Key Laboratory of Human Disease Genomics the Swedish Government (CancerUU) the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10